External components

By adding polyethylene glycol or glycerin to adapalene compositions, the discomfort caused by adapalene application is mitigated, addressing the issue of irritation and burning sensation, thereby enhancing treatment adherence.

JP2026182822APending Publication Date: 2026-11-19ROHTO PHARM CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2026078083
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-07
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Retinoids like adapalene cause discomfort upon application, such as irritation and burning sensation, leading to decreased treatment adherence, and combining adapalene with humectants like polyhydric alcohols exacerbates this discomfort.

Method used

Incorporating polyethylene glycol or glycerin into adapalene-containing compositions to reduce the enhancement of discomfort during application.

Benefits of technology

The inclusion of polyethylene glycol or glycerin in adapalene compositions significantly reduces the discomfort associated with its application, as measured by TRPV1 activity, providing a more tolerable treatment experience.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026182822000001
    Figure 2026182822000001
  • Figure 2026182822000002
    Figure 2026182822000002
  • Figure 2026182822000003
    Figure 2026182822000003
Patent Text Reader

Abstract

To provide a topical composition containing adapalene and a humectant that reduces the increased discomfort caused by adapalene during application. [Solution] A topical composition containing (A) adapalene and (B) one or more selected from the group consisting of polyethylene glycol and glycerin.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This invention relates to an external composition. [Background technology]

[0002] Adapalene and other retinoids are used in pharmaceutical acne medications. For example, Patent Document 1 discloses a pharmaceutical composition containing adapalene and tranexamic acid or a salt thereof. Patent Document 1 also states that this pharmaceutical composition is highly effective against acne. [Prior art documents] [Patent Documents]

[0003] [Patent Document 1] Japanese Patent Publication No. 2015-081244 [Overview of the project] [Problems that the invention aims to solve]

[0004] However, it has been reported that retinoids frequently cause discomfort (e.g., irritation and burning sensation) upon application, which has led to decreased treatment adherence to pharmaceutical compositions containing retinoids. However, the reasons for discomfort when applying retinoids such as adapalene are not well understood. Currently, the only countermeasures taken are to recommend moisturizing when using retinoids.

[0005] On the other hand, when adapalene is used, if a humectant (mainly a polyhydric alcohol) is added to the adapalene-containing composition to provide moisturizing effects, the humectant itself may cause discomfort during application. It has also been newly discovered that using adapalene and the humectant together can exacerbate this discomfort.

[0006] Therefore, the present invention aims to provide a topical composition containing adapalene and a moisturizer in which the enhancement of discomfort during application caused by adapalene is reduced. [Means for solving the problem]

[0007] The inventors have found that by including polyethylene glycol or glycerin in a composition containing adapalene, the enhancement of discomfort during application caused by adapalene is reduced. This invention is based on this finding.

[0008] The present invention includes, for example, the following inventions: [1] A topical composition containing (A) adapalene and (B) one or more selected from the group consisting of polyethylene glycol and glycerin. [2] The topical composition described in [1], containing 0.001 to 1% by weight of component (A) above. [3] The topical composition according to [1] or [2], containing 0.001 to 30% by weight of component (B) above. [4] The topical composition according to any one of [1] to [3], wherein the ratio of the content (weight%) of component (B) to the content (weight%) of component (A) is 0.001 to 300. [5] A method for imparting to a composition containing (A) adapalene an effect that reduces the enhancement of discomfort during application caused by the above component (A), comprising (B) adding one or more selected from the group consisting of polyethylene glycol and glycerin. [6] A method for reducing the enhancement of discomfort caused by component (A) during application in a composition comprising (A) a composition containing adapalene and (B) one or more selected from the group consisting of polyethylene glycol and glycerin. [7] An agent for enhancing or reducing discomfort during application of an adapalene-containing topical composition containing one or more selected from the group consisting of polyethylene glycol and glycerin. [Effects of the Invention]

[0009] According to the present invention, it is possible to provide a topical composition containing adapalene and a moisturizer in which the enhancement of discomfort during application caused by adapalene is reduced. [Modes for carrying out the invention]

[0010] The following describes in detail embodiments for carrying out the present invention. However, the present invention is not limited to the following embodiments.

[0011] The external composition according to this embodiment contains (A) adapalene (hereinafter also referred to as "component (A)") and (B) one or more selected from the group consisting of polyethylene glycol and glycerin (hereinafter also referred to as "component (B)").

[0012] Adapalene has been reported to frequently cause discomfort (e.g., irritation and burning sensation) upon application. Hereinafter, "discomfort upon application" means any unpleasant sensation that occurs when adapalene is applied to the skin, and may include, for example, irritation, burning, itching, pain, tingling, stinging, or prickling. Discomfort upon application often does not involve visible changes such as erythema or edema, and sensory irritation is the main symptom.

[0013] TRPV1 (Transient receptor potential cation channel subfamily V member 1) is known to be activated by stimuli such as capsaicin, heat above 43°C, and acids. When TRPV1 is activated by the above stimuli, calcium ions (Ca) are released. 2+ ) flows into the cell, and the incoming calcium ions activate the anion channel anoctamin 1. Upon activation of anoctamin 1, chloride ions (Cl- It is thought that when ) flows from inside the cell to outside the cell, the membrane potential changes in the positive direction, causing sensory nerves to be excited and resulting in the sensation of pain and burning. Furthermore, TRPV1 is known to be involved in pain and burning caused by several retinoids. In addition, TRPV1 activity is also involved in the discomfort caused by adapalene. This was previously unknown and is a new finding obtained by the present inventors.

[0014] Furthermore, in this specification, "reducing the enhancement of discomfort during application by adapalene" means that the difference between the degree of discomfort during application when using adapalene alone and the degree of discomfort during application when using a combination of adapalene and propylene glycol is reduced, compared to the difference between the degree of discomfort during application when using adapalene alone and the degree of discomfort during application when using adapalene and propylene glycol in combination. The degree of discomfort during application may be, for example, the degree of TRPV1 activity. The method for evaluating TRPV1 activity will be described later.

[0015] For example, the TRPV1 activity of a composition containing propylene glycol, which is widely blended in component (A) and external compositions, synergistically increases (enhances) compared to the TRPV1 activity of a composition containing only component (A) (see, for example, Table 1 and Table 2 in the Examples). On the other hand, the TRPV1 activity of the external composition containing component (A) and component (B) is lower than the TRPV1 activity of the composition containing component (A) and propylene glycol (see, for example, Tables 1 to 3 in the Examples). That is, component (B) reduces the enhancement of TRPV1 activity by component (A). The external composition according to the present embodiment has reduced enhancement of discomfort during application caused by component (A). As described above, the present inventors have found that the humectant itself may also cause discomfort during application. Therefore, by selecting a humectant that does not significantly increase discomfort during application even when combined with adapalene, compared to the case of adapalene alone, an external composition with a low degree of discomfort during application can be prepared.

[0016] <Component (A)> Adapalene is a compound also referred to as 6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid. The content of component (A) in the external composition according to the present embodiment is not particularly limited, and is appropriately set according to the types and contents of other blended components, the use and formulation form of the external composition, and the like. The content of component (A) in the external composition according to the present embodiment is, for example, 0.0001% by weight or more, 0.0002% by weight or more, 0.0004% by weight or more, 0.0005% by weight or more, 0.001% by weight or more, 0.005% by weight or more, 0.01% by weight or more, 0.02% by weight or more, 0.03% by weight or more, 0.04% by weight or more, 0.05% by weight or more, 0.06% by weight or more, 0.07% by weight or more, 0.08% by weight or more, 0.09% by weight or more, 0.1% by weight or more, based on the total amount of the external composition according to the present embodiment, and may be 1% by weight or less, 0.9% by weight or less, 0.8% by weight or less, 0.7% by weight or less, 0.6% by weight or less, 0.5% by weight or less, 0.4% by weight or less, 0.3% by weight or less, 0.2% by weight or less, or 0.1% by weight or less. The content of component (A) in the external composition according to the present embodiment may be, for example, 0.0001 to 1% by weight, 0.001 to 1% by weight, 0.005 to 0.9% by weight, 0.01 to 0.7% by weight, 0.05 to 0.5% by weight, or 0.1 to 0.25% by weight, based on the total amount of the external composition according to the present embodiment.

[0017] <Component (B)> The number average molecular weight of polyethylene glycol is not particularly limited, and for example, may be 200 or more, 400 or more, 600 or more, 1000 or more, 4000 or more, 6000 or more, or 8000 or more, and may be 20000 or less, 8000 or less, 6000 or less, 4000 or less, 1000 or less, 600 or less, or 400 or less.

[0018] When the topical composition according to this embodiment contains polyethylene glycol (PEG), the content of polyethylene glycol in the topical composition according to this embodiment is not particularly limited and can be appropriately set depending on the type and content of other components, the use of the topical composition, and the formulation form. The polyethylene glycol content in the external composition according to this embodiment may be, for example, 0.01% by weight or more, 0.02% by weight or more, 0.03% by weight or more, 0.04% by weight or more, 0.05% by weight or more, 0.06% by weight or more, 0.07% by weight or more, 0.08% by weight or more, 0.09% by weight or more, 0.1% by weight or more, 0.2% by weight or more, 0.3% by weight or more, 0.4% by weight or more, 0.5% by weight or more, 1% by weight or more, 2% by weight or more, 3% by weight or more, 4% by weight or more, or 5% by weight or more, based on the total amount of the external composition according to this embodiment. The polyethylene glycol content in the topical composition according to this embodiment may be, for example, 0.001 to 50% by weight, 0.1 to 30% by weight, 0.5 to 10% by weight, 1 to 5% by weight, or 1 to 3% by weight, based on the total amount of the topical composition according to this embodiment.

[0019] Glycerin is a compound also known as 1,2,3-propanetriol. When the topical composition according to this embodiment contains glycerin, the glycerin content in the topical composition according to this embodiment is not particularly limited and can be appropriately set depending on the type and content of other ingredients, the use of the topical composition, and the formulation form. The glycerin content in the topical composition according to this embodiment may be, for example, 0.01% by weight or more, 0.02% by weight or more, 0.03% by weight or more, 0.04% by weight or more, 0.05% by weight or more, 0.06% by weight or more, 0.07% by weight or more, 0.08% by weight or more, 0.09% by weight or more, 0.1% by weight or more, 0.2% by weight or more, 0.3% by weight or more, 0.4% by weight or more, 0.5% by weight or more, 1% by weight or more, 2% by weight or more, 3% by weight or more, 4% by weight or more, or 5% by weight or more, based on the total amount of the topical composition according to this embodiment. The glycerin content in the topical composition according to this embodiment may be, for example, 0.001 to 50% by weight, 0.1 to 30% by weight, 0.5 to 10% by weight, 1 to 5% by weight, or 1 to 3% by weight, based on the total amount of the topical composition according to this embodiment.

[0020] Component (B) may be used alone or in combination of two or more types. Component (B) is preferably polyethylene glycol.

[0021] The content of component (B) in the topical composition according to this embodiment is not particularly limited. For example, based on the total amount of the topical composition according to this embodiment, it may be 0.001% by weight or more, 0.002% by weight or more, 0.003% by weight or more, 0.004% by weight or more, 0.005% by weight or more, 0.006% by weight or more, 0.007% by weight or more, 0.008% by weight or more, 0.009% by weight or more, 0.01% by weight or more, 0.02% by weight or more, 0.03% by weight or more, 0.04% by weight or more, 0.05% by weight or more, 0.06% by weight or more, 0.07% by weight or more, 0.08% by weight or more, 0.09% by weight or more, 0.1% by weight or more, 0.2% by weight or more. It may be 1% or more by weight, 0.3% or more by weight, 0.4% or more by weight, 0.5% or more by weight, 1% or more by weight, 2% or more by weight, 3% or more by weight, 4% or more by weight, or 5% or more by weight, and it may also be 70% or less by weight, 60% or less by weight, 50% or less by weight, 40% or less by weight, 30% or less by weight, 20% or less by weight, 15% or less by weight, 10% or less by weight, 5% or less by weight, 4% or less by weight, 3% or less by weight, 2% or less by weight, 1% or less by weight, 0.9% or less by weight, 0.8% or less by weight, 0.7% or less by weight, 0.6% or less by weight, 0.5% or less by weight, 0.4% or less by weight, 0.3% or less by weight, 0.2% or less by weight, or 0.1% or less by weight. The content of component (B) in the topical composition according to this embodiment may be, for example, 0.001 to 50% by weight, 0.005 to 20% by weight, 0.01 to 10% by weight, 0.1 to 5% by weight, or 1 to 3% by weight, based on the total amount of the topical composition according to this embodiment.

[0022] In the external composition according to this embodiment, the ratio of the content (weight%) of component (B) to the content (weight%) of component (A) (content of (B) / content of (A)) may be, for example, 0.001 or more, 0.005 or more, 0.01 or more, 0.05 or more, 0.1 or more, 0.5 or more, 1 or more, 5 or more, 10 or more, 15 or more, 20 or more, or 25 or more, and may be 300 or less, 290 or less. The following are also acceptable: below 280, below 270, below 260, below 250, below 240, below 230, below 220, below 210, below 200, below 190, below 180, below 170, below 160, below 150, below 140, below 130, below 120, below 110, below 100, below 90, below 80, below 70, below 60, below 50, below 40, below 30, below 20, or below 10. In the external composition according to this embodiment, the ratio of the content of component (B) (weight%) to the content of component (A) (content of component (B) / content of component (A)) may be, for example, 0.001 to 300, 0.05 to 250, 0.1 to 200, 0.5 to 150, 1 to 100, 5 to 50, 10 to 45, 15 to 35, 20 to 30, or 25 to 30. Alternatively, in the external composition according to this embodiment, the content of component (B) / content of component (A) may be, for example, 0.001 to 300, 0.05 to 250, 0.1 to 200, 0.5 to 150, 1 to 100, 2 to 90, 3 to 80, 4 to 70, 5 to 60, or 10 to 50.

[0023] In the topical composition according to this embodiment, the discomfort caused by component (A) during application can be evaluated by evaluating the activity of TRPV1. TRPV1 activation can be evaluated, for example, by the method described in the examples below. Specifically, for example, intracellular Ca2+ ionization caused by the activation of TRPV1 2+ The increase in concentration, Ca 2+ It can be evaluated by measuring using a sensitive fluorescent dye.

[0024] The external composition according to this embodiment may have a TRPV1 activity of 0.95 or less, 0.9 or less, 0.85 or less, 0.8 or less, 0.75 or less, or 0.7 or less, when the TRPV1 activity of a composition containing adapalene and propylene glycol is set to 1.

[0025] The external composition according to this embodiment may contain a thickening agent and / or an irritation-reducing agent, to the extent that it does not impair the effects of the present invention.

[0026] Examples of thickening agents include cellulosic polymers such as ethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, carboxymethylcellulose, and carboxyethylcellulose; vinyl polymers such as polyvinylpyrrolidone, carboxyvinyl polymer, polyvinyl alcohol, and alkyl acrylate methacrylate copolymer; natural polymer derivatives such as cationized guar gum and acetylated hyaluronic acid; natural polymers such as carrageenan, alginic acid, cellulose, guar gum, quince seed, dextran, gellan gum, hyaluronic acid, and chondroitin sulfate; polyvinyl butyrate; polyethylene glycol; polysaccharides such as dextrin and maltodextrin; locust bean gum; xanthan gum; and bentonite.

[0027] The content of the thickening agent in the topical composition according to this embodiment may be 0.001% by weight or more, 0.01% by weight or more, 0.05% by weight or more, 0.1% by weight or more, 0.2% by weight or more, 0.3% by weight or more, or 0.5% by weight or more, based on the total amount of the topical composition, and may also be 5% by weight or less, 3% by weight or less, 2% by weight or less, 1.5% by weight or less, 1% by weight or less, or 0.5% by weight or less. The content of the thickening agent in the topical composition according to this embodiment may be, for example, 0.001 to 5% by weight, 0.01 to 3% by weight, 0.1 to 1% by weight, or 0.3 to 0.5% by weight, based on the total amount of the topical composition.

[0028] In the external composition according to this embodiment, the ratio of the content of the thickener (weight%) to the content of component (A) (content of thickener / content of component (A)) may be, for example, 0.01 or more, 0.05 or more, 0.1 or more, 0.2 or more, 0.3 or more, 0.5 or more, 1 or more, 3 or more, or 5 or more, and may also be 50 or less, 30 or less, 20 or less, 15 or less, 10 or less, or 5 or less. The content of the thickener / content of component (A) may be, for example, 0.001 to 50, 0.01 to 40, 0.05 to 30, 0.1 to 20, 0.5 to 10, or 1 to 5.

[0029] Examples of irritation-reducing agents include terpenoids or their derivatives, zinc salts, parabens, ethylenediaminetetraacetic acid or its salts, and flavonols.

[0030] Terpenoids are compounds that consist of one or more isoprene units as constituent units. Terpenoids may be, for example, hemiterpenoids, monoterpenoids, sesquiterpenoids, diterpenoids, cesaterpenoids, triterpenoids, tetraterpenoids, or polyterpenoids, but monoterpenoids are preferred.

[0031] Examples of terpenoid derivatives include compounds in which one or more groups selected from the group consisting of nonionic water-soluble functional groups, cationic functional groups, anionic functional groups, and hydrophobic groups are introduced into a terpenoid, and salts of such compounds. Examples of nonionic water-soluble functional groups include hydroxyl groups, ketone groups, ester groups, and ether groups. Examples of cationic functional groups include amino groups. Examples of anionic functional groups include carboxyl groups. Examples of hydrophobic groups include aldehyde groups. Preferably, terpenoid derivatives are compounds in which a nonionic water-soluble functional group is introduced into a terpenoid, and salts thereof, and more preferably compounds in which a hydroxyl group is introduced into a terpenoid.

[0032] The terpenoid or its derivative may specifically be, for example, menthol, camphor, borneol, geraniol, cineole, pinene, ρ-menthane-3,8-diol, and menthol and / or ρ-menthane-3,8-diol.

[0033] If optical isomers exist, the terpenoid or its derivative may be the d-isomer, l-isomer, or dl-isomer. The terpenoid or its derivative may be a purified form, or a substance containing the terpenoid or its derivative may be used. Examples of substances containing the terpenoid or its derivative include essential oils containing the terpenoid or its derivative. Essential oils are oils extracted from plants that contain aromatic components. Examples of essential oils containing the terpenoid or its derivative include eucalyptus oil, bergamot oil, peppermint oil, fennel oil, rose oil, cinnamon oil, spearmint oil, and camphor oil, with eucalyptus oil being preferred.

[0034] The zinc salt can be any pharmaceutically acceptable zinc salt, such as zinc sulfate, zinc chloride, zinc nitrate, zinc carbonate, zinc acetate, zinc gluconate, or zinc oxide, with zinc sulfate being preferred. The zinc salt may also be a hydrate (for example, zinc sulfate heptahydrate (zinc sulfate hydrate)).

[0035] Parabens are a general term for parahydroxybenzoic acid esters. Specific examples of parabens include methyl parahydroxybenzoate (methylparaben), ethyl parahydroxybenzoate (ethylparaben), propyl parahydroxybenzoate (propylparaben), isopropyl parahydroxybenzoate (isopropylparaben), n-butyl parahydroxybenzoate (n-butylparaben), isobutyl parahydroxybenzoate (isobutylparaben), phenyl parahydroxybenzoate (phenylparaben), pentyl parahydroxybenzoate (pentylparaben), and parahydroxy Examples include hexyl benzoate (hexylparaben), heptyl parahydroxybenzoate (heptylparaben), n-octyl parahydroxybenzoate (n-octylparaben), isooctyl parahydroxybenzoate (isooctylparaben), and benzyl parahydroxybenzoate (benzylparaben). Methyl parahydroxybenzoate (methylparaben) and propyl parahydroxybenzoate (propylparaben) are preferred, and methyl parahydroxybenzoate (methylparaben) is more preferred.

[0036] The salt of ethylenediaminetetraacetic acid (EDTA) can be any pharmaceutically acceptable salt of ethylenediaminetetraacetic acid, such as alkali metal salts of ethylenediaminetetraacetic acid (e.g., disodium ethylenediaminetetraacetic acid (sodium EDTA), tetrasodium ethylenediaminetetraacetic acid, dipotassium ethylenediaminetetraacetic acid, tetrapotassium ethylenediaminetetraacetic acid, etc.) and alkaline earth metal salts of ethylenediaminetetraacetic acid (e.g., disodium calcium ethylenediaminetetraacetic acid, disodium magnesium ethylenediaminetetraacetic acid, etc.), with disodium ethylenediaminetetraacetic acid (sodium EDTA) being preferred. The salt of ethylenediaminetetraacetic acid (EDTA) may also be a hydrate (e.g., disodium ethylenediaminetetraacetic acid hydrate (sodium EDTA hydrate)).

[0037] Flavonols are a group of flavonoid compounds that have a 3-hydroxyflavone (3-hydroxy-2-phenylchromen-4-one) skeleton. Flavonols may be derived from natural products (plants, microorganisms, etc.) or artificially synthesized.

[0038] Examples of flavonols include 3-hydroxyflavone, azareatin, fisetin, galangin, gossipetin, kaemperia, kaemperool, isorhamnetin, morin, myricetin, natsudaidain, pachypodol, quercetin, rhamnadin, ramnetin, and tamarixetin, with quercetin being preferred.

[0039] The irritation-reducing agent is preferably one or more selected from the group consisting of menthol, ρ-menthane-3,8-diol, zinc sulfate, methylparaben, disodium ethylenediaminetetraacetate, eucalyptus oil, and quercetin.

[0040] The content of the irritation-reducing agent in the topical composition according to this embodiment is not particularly limited. For example, based on the total amount of the topical composition according to this embodiment, the amounts may be 0.00001% by weight or more, 0.00003% by weight or more, 0.0001% by weight or more, 0.0003% by weight or more, 0.001% by weight or more, 0.002% by weight or more, 0.003% by weight or more, 0.004% by weight or more, 0.005% by weight or more, 0.006% by weight or more, 0.007% by weight or more, 0.008% by weight or more, 0.009% by weight or more, 0.01% by weight or more, and 0.0 It may be 2% by weight or more, 0.03% by weight or more, 0.04% by weight or more, 0.05% by weight or more, 0.06% by weight or more, 0.07% by weight or more, 0.08% by weight or more, 0.09% by weight or more, 0.1% by weight or more, 0.2% by weight or more, 0.3% by weight or more, 0.4% by weight or more, or 0.5% by weight or more, and it may also be 5% by weight or less, 3% by weight or less, 1% by weight or less, 0.8% by weight or less, 0.6% by weight or less, 0.5% by weight or less, 0.4% by weight or less, 0.3% by weight or less, 0.2% by weight or less, or 0.1% by weight or less. The content of the irritation-reducing agent in the topical composition according to this embodiment may be, for example, 0.00001 to 1% by weight, 0.001 to 1% by weight, 0.005 to 0.9% by weight, 0.01 to 0.7% by weight, or 0.05 to 0.5% by weight, based on the total amount of the topical composition according to this embodiment.

[0041] In the external composition according to this embodiment, the ratio of the content of the irritation-reducing agent (weight%) to the content of component (A) (content of irritation-reducing agent / content of component (A)) is, for example, 0.001 or more, 0.005 or more, 0.01 or more, 0.02 or more, 0.024 or more, 0.05 or more, 0.06 or more, 0.07 or more, 0.073 or more, 0.1 or more, 0.2 or more, 0.24 or more, 0.25 or more, 0.5 or more, 0.6 or more, 0.7 or more, 0.73 or more, 1 or more, 1.5 or more, 2 The above may be 2.4 or higher, 2.42 or higher, 5 or higher, 6 or higher, 7 or higher, 7.27 or higher, 10 or higher, 15 or higher, 20 or higher, or 25 or higher, and may also be 100 or lower, 95 or lower, 90 or lower, 85 or lower, 80 or lower, 75 or lower, 70 or lower, 65 or lower, 60 or lower, 55 or lower, 50 or lower, 45 or lower, 40 or lower, 35 or lower, 30 or lower, 25 or lower, 20 or lower, 18 or lower, 15 or lower, 10 or lower, 9 or lower, 8 or lower, 7.5 or lower, 7.3 or lower, 7.27 or lower, 7 or lower, or 5 or lower. In the external composition according to this embodiment, the ratio of the content of the irritation-reducing agent (weight%) to the content of component (A) (content of irritation-reducing agent / content of component (A)) may be, for example, 0.001 to 50, 0.05 to 50, 0.1 to 45, 0.5 to 45, 1 to 40, 5 to 40, 10 to 35, 15 to 35, 20 to 30, or 25 to 30. Alternatively, in the topical composition according to this embodiment, the ratio of the content of the irritation-reducing agent (weight%) to the content of component (A) (content of irritation-reducing agent / content of component (A)) may be, for example, 0.001 to 50, 0.01 to 40 (for example, 0.02 to 10, 0.02 to 9, 0.02 to 8, 0.02 to 7.5, or 0.02 to 7), 0.05 to 30, 0.1 to 20, 0.5 to 10, or 1 to 5.

[0042] The external composition according to this embodiment may be a pharmaceutical, a quasi-drug, or a cosmetic. Preferably, the external composition according to this embodiment is a skin external composition applied to the skin.

[0043] The form of the topical composition according to this embodiment used for pharmaceutical purposes is not particularly limited, and examples include liquids, suspensions, emulsions, creams, ointments, gels, liniments, lotions, aerosols, etc. These formulations can be manufactured according to the methods described in the General Provisions of the 18th Revised Japanese Pharmacopoeia. Among the forms of the topical composition according to this embodiment, liquids, suspensions, emulsions, creams, ointments, gels, lotions, and aerosols are preferred, and liquids, suspensions, creams, emulsions, and gels are more preferred.

[0044] When the external composition according to this embodiment is used as an external composition for quasi-drugs or cosmetics, it can be in the same form as the external composition for pharmaceuticals described above. In addition, other forms of the external composition according to this embodiment include stick formulations or sheet formulations in which the drug solution is impregnated into a nonwoven fabric. Among the forms of external compositions used as quasi-drugs or cosmetics, liquid formulations, suspension formulations, emulsion formulations, cream formulations, ointment formulations, gel formulations, lotion formulations and sheet formulations are preferred, with liquid formulations, suspension formulations, cream formulations, emulsion formulations and gel formulations being more preferred.

[0045] When the external composition according to this embodiment is used as an external composition for quasi-drugs or cosmetics, examples of its uses include basic cosmetics such as lotions, emulsions, gels, creams, serums, sunscreens, packs, masks, hand creams, body lotions, and body creams; cleansing cosmetics such as facial cleansers, makeup removers, shaving agents, body shampoos, shampoos, conditioners, and treatments; makeup cosmetics such as foundations and mascaras; hair removal agents; and bath additives.

[0046] In addition to the above-mentioned components, the external composition according to this embodiment may contain bases or carriers commonly used in pharmaceuticals, quasi-drugs, or cosmetics. Furthermore, the external composition according to this embodiment may contain additives as needed.

[0047] The base or carrier contained in the external composition according to this embodiment may include, for example, hydrocarbons such as liquid paraffin, squalane, petrolatum, gelling hydrocarbons (such as Plastibase), ozokerite, α-olefin oligomers, and light liquid paraffin; methylpolysiloxane, crosslinked methylpolysiloxane, highly polymerized methylpolysiloxane, cyclic silicone, alkyl-modified silicone, crosslinked alkyl-modified silicone, amino-modified silicone, polyether-modified silicone, polyglycerin-modified silicone, crosslinked polyether-modified silicone, crosslinked alkyl polyether-modified silicone, silicone-alkyl chain-comodified polyether-modified silicone, silicone-alkyl chain-comodified polyglycerin-modified silicone, polyether-modified branched silicone, polyglycerin-modified branched silicone, acrylic silicone, phenyl-modified silicone, and silicone resin; cetanol, cetostearyl alcohol, stearyl Alcohols, higher alcohols such as behenyl alcohol; cholesterol, sterols such as phytosterols and phytosteryl hydroxystearate; vegetable oils such as jojoba oil, meadowfoam oil, sunflower oil, grape seed oil, camellia oil, squalane, shea butter, and rice germ oil; animal oils such as lanolin, orange roughy oil, squalane, and horse oil; polyvinyl butyrate; dioxane; butylene glycol adipate polyester; isopropyl myristate, myris Examples of suitable bases or carriers include octyldodecyl tinate, isopropyl palmitate, cetyl palmitate, isononyl isononanoate, pentaerythritol tetra-2-ethylhexanoate, jojoba oil, esters such as caprylic / capric triglyceride; lower alcohols such as ethanol and isopropanol; polyhydric alcohols having 2 to 6 carbon atoms and 2 to 4 hydroxyl groups; glycol ethers; organic acids such as succinic acid, glycolic acid, gluconic acid, and citric acid; and aqueous bases such as water. Among the bases or carriers contained in the external composition according to this embodiment, polyhydric alcohols, higher alcohols, hydrocarbons, esters, and silicone oils are preferred, with polyhydric alcohols being more preferred.

[0048] Preferred examples of the external composition according to this embodiment include liquid formulations, suspensions, creams, emulsions, and gels containing a polyhydric alcohol as a base.

[0049] The base or carrier may be used individually or in combination of two or more types.

[0050] The external composition according to this embodiment may contain known additives used in pharmaceuticals, quasi-drugs, or cosmetics, as long as they do not impair the effects of the present invention. Examples of additives include antioxidants, surfactants, preservatives, pH adjusters, stabilizers, antiseptics, colorants, cooling agents, fragrances, and pearlescent agents.

[0051] Examples of antioxidants include dibutylhydroxytoluene, butylhydroxyanisole, sorbic acid, sodium sulfite, ascorbic acid, ascorbic acid derivatives, tocopherol, tocopherol derivatives, erythorbic acid, and L-cysteine ​​hydrochloride.

[0052] Examples of surfactants include sorbitan fatty acid esters such as sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan penta-2-ethylhexyl diglycerol sorbitan, and tetra-2-ethylhexyl diglycerol sorbitan; propylene glycol fatty acid esters such as propylene glycol monostearate; polyoxyethylene hydrogenated castor oil 40 (HCO-40), polyoxyethylene hydrogenated castor oil 50 (HCO-50), Hydrogenated castor oil derivatives such as polyoxyethylene hydrogenated castor oil 60 (HCO-60) and polyoxyethylene hydrogenated castor oil 80; polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene (20) sorbitan monolauryl acid (polysorbate 20), polyoxyethylene (20) sorbitan monostearate (polysorbate 60), polyoxyethylene (20) sorbitan monooleate (polysorbate 80), and polyoxyethylene (20) sorbitan isostearate; polyoxyethylene monococonut oil Examples include fatty acid glyceryls; glycerin alkyl ethers; alkyl glucosides such as cetostearyl glucoside; polyoxyalkylene alkyl ethers such as polyoxyethylene cetyl ether, polyoxyethylene behenyl ether, and polyoxyethylene polyoxypropylene glycol (e.g., polyoxyethylene(20) polyoxypropylene(20) glycol); amines such as stearylamine and oleylamine; silicone-based surfactants such as polyoxyethylene methylpolysiloxane copolymer, lauryl PEG-9 polydimethylsiloxyethyl dimethicone, and PEG-9 polydimethylsiloxyethyl dimethicone; natural surfactants such as phospholipids, surfactin, and saponins; fatty acid amidoamines such as diethylaminoethyl stearate and diethylaminopropyl stearate; alkylamines such as trilaurylamine, dimethylstearylamine, and di-2-ethylhexylamine; and betaine-based amphoteric surfactants such as dimethylaminopropyl stearate and lauryl hydroxysulfobetaine.

[0053] Examples of preservatives include benzoic acid, sodium benzoate, dehydroacetic acid, sodium dehydroacetate, phenoxyethanol, benzyl alcohol, chlorobutanol, sorbic acid and its salts, chlorhexidine gluconate, alkanediols, and glycerin fatty acid esters.

[0054] Examples of pH adjusters include inorganic acids (hydrochloric acid, sulfuric acid, phosphoric acid, polyphosphate, boric acid, etc.), organic acids (lactic acid, sodium lactate, acetic acid, citric acid, sodium citrate, tartaric acid, malic acid, succinic acid, sodium succinate, oxalic acid, gluconic acid, fumaric acid, propionic acid, aspartic acid, epsilonaminocaproic acid, glutamic acid, aminoethylsulfonic acid, etc.), gluconolactone, ammonium acetate, inorganic bases (sodium bicarbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide, etc.), and organic bases (monoethanolamine, triethanolamine, diisopropanolamine, lysine, triisopropanolamine, etc.).

[0055] Examples of stabilizers include sodium polyacrylate, dibutylhydroxytoluene, and butylhydroxyanisole.

[0056] Examples of chelating agents include phytic acid, gluconic acid, polyphosphate, and metaphosphate.

[0057] Examples of colorants include inorganic pigments and natural dyes.

[0058] Examples of cooling agents include monomenthyl glyceryl ether, menthyl lactate, eugenol, mint oil, and peppermint oil.

[0059] Examples of pearlescent luster imparters include ethylene glycol distearate, ethylene glycol monostearate, and triethylene glycol distearate. Ethylene glycol distearate is preferred as the pearlescent luster imparter.

[0060] Additives may be used individually or in combination of two or more types.

[0061] The topical composition according to this embodiment may contain other components as long as they do not impair the effects of the present invention. Specific examples of such components include, for example, moisturizing components, anti-inflammatory components, antibacterial components, vitamins, peptides or their derivatives, amino acids or their derivatives, cell-activating components, anti-aging components, blood circulation-promoting components, keratin-softening components, whitening components, astringent components, and UV protection components (UV-absorbing components, UV-scattering components).

[0062] Moisturizing ingredients include, for example, lipids such as ceramides, cholesterol, and phospholipids; plant extracts such as chamomile extract, mulberry extract, houttuynia cordata extract, carrot extract, witch hazel extract, bilberry leaf extract, tea extract, and perilla extract; mucopolysaccharides such as hyaluronic acid, sodium hyaluronate, acetylated hyaluronic acid, sodium acetylated hyaluronate, heparin-like substances, chondroitin, and sodium chondroitin sulfate; high molecular weight compounds such as collagen, elastin, keratin, chitin, and chitosan; polyhydric alcohols such as butylene glycol (BG), dipropylene glycol (DPG), diglycerin, and trehalose; alanine, ce Examples of moisturizers include amino acids such as phosphorus, leucine, isoleucine, threonine, glycine, proline, hydroxyproline, glucosamine, aspartic acid, theanine, and arginine; natural moisturizing factors such as sodium lactate, urea, and sodium pyrrolidone carboxylate; sugar alcohols such as sorbitol; phospholipids such as lecithin and hydrogenated lecithin; polyglutamic acid; polymers having phospholipid polar groups such as MPC polymers (e.g., LIPIDURE®); polyoxypropylene methyl glucoside; trimethylglycine (betaine); hydroxyethyl urea; and acrylic acid / acrylamide / dimethyldiallylammonium chloride copolymers. Among moisturizers, lipids such as ceramide, cholesterol, and phospholipids are preferred, considering the feel of use; and plant extracts such as mulberry extract, Houttuynia cordata extract, carrot extract, and bilberry leaf extract are preferred.

[0063] Examples of anti-inflammatory components include those derived from plants (e.g., grapes, ginseng, and comfrey), allantoin, glycyrrhizic acid or its derivatives, pyridoxine hydrochloride, salicylic acid or its derivatives, and ε-aminocaproic acid, proanthocyanidins, tocopherol or its derivatives, ascorbic acid or its derivatives, hesperidin, glucosyl hesperidin, ergothioneine, sodium bisulfite, erythorbic acid or its salts, flavonoids, glutathione, glutathione peroxidase, glutathione-S-transferase, catalase, superoxide dismutase, thioredoxin, taurine, thiotaurine, hypotaurine, and others.

[0064] Examples of antibacterial or bactericidal components include chlorhexidine, salicylic acid, benzalkonium chloride, acrinol, sulfur, resorcinol, ethanol, benzethonium chloride, benzoyl peroxide, clindamycin, cresol, gluconic acid and its derivatives, povidone-iodine, potassium iodide, iodine, isopropylmethylphenol, triclocarban, triclosan, photosensitizer 101, photosensitizer 201, parabens, phenoxyethanol, alkanediols such as 1,2-pentanediol, glycerin fatty acid esters, azelaic acid, alkyldiaminoglycine hydrochloride, chlorhexidine gluconate, and zinc paraphenolsulfonate. The topical composition according to this embodiment may not contain benzoyl peroxide.

[0065] Examples of vitamins include retinol derivatives such as retinol, retinyl acetate, and retinyl palmitate; vitamin A derivatives such as retinal, retinoic acid, methyl retinoate, ethyl retinoate, retinyl retinoate, d-δ-tocopheryl retinoate, α-tocopheryl retinoate, and β-tocopheryl retinoate; and β-carotene, α-carotene, γ-carotene, δ-carotene, lycopene, zeaxanthin, and cryptoxanthin. Provitamin A compounds such as echinenone; Vitamin E compounds such as δ-tocopherol, dl-α-tocopherol, dl-α-tocopherol acetate, dl-α-tocopherol succinate, dl-α-tocopherol calcium succinate, and tocopherol nicotinate; Riboflavin, flavin mononucleotide, flavin adenine dinucleotide, riboflavin butyrate, riboflavin tetrabutyrate, and riboflavin 5'-phosphate sodium Vitamin B2 compounds such as riboflavin tetranicotinate; nicotinic acid compounds such as nicotinic acid, nicotinamide, dl-α-tocopherol nicotinate, benzyl nicotinate, methyl nicotinate, β-butoxyethyl nicotinate, and 1-(4-methylphenyl)ethyl nicotinate; vitamin C compounds such as ascorbyl stearate, L-ascorbyl dipalmitate, ascorbyl tetraisopalmitate (tetra-2-hexyldecanoate ascorbyl), ascorbic acid, sodium ascorbate, dehydroascorbic acid, sodium ascorbate phosphate, magnesium ascorbate phosphate, ascorbic acid glucoside, ascorbigen-A, ascorbic acid stearate, and ascorbic acid palmitate; vitamin D compounds such as methylhesperidin, ergocalciferol, and cholecalciferol; vitamin K compounds such as phylloquinone and phylloquinone;Vitamin B1 compounds such as dibenzoylthiamine, dibenzoylthiamine hydrochloride, thiamine hydrochloride, thiamine cetyl hydrochloride, thiamine thiocyanate, thiamine lauryl hydrochloride, thiamine nitrate, thiamine monophosphate, thiamine lysine salt, thiamine triphosphate, thiamine monophosphate phosphate, thiamine monophosphate, thiamine diphosphate, thiamine diphosphate hydrochloride, thiamine triphosphate, thiamine triphosphate monophosphate; pyridoxine hydrochloride, pyridoxine acetate, pyridoxal hydrochloride, 5'-phosphate Examples include vitamin B6 compounds such as pyridoxal and pyridoxamine hydrochloride; vitamin B12 compounds such as cyanocobalamin, hydroxocobalamin, and deoxyadenosylcobalamin; folic acid compounds such as folic acid and pteroylglutamic acid; pantothenic acid compounds such as pantothenic acid, calcium pantothenate, pantothenyl alcohol (panthenol), D-panthesine, D-pantethine, coenzyme A, and pantothenyl ethyl ether; biotin compounds such as biotin and biotisine; and vitamin-like factors such as γ-oryzanol, carnitine, ferulic acid, α-lipoic acid, and orotic acid.

[0066] Examples of peptides or their derivatives include keratin-degrading peptides, hydrolyzed keratin, collagen, fish-derived collagen, atelocollagen, gelatin, elastin, elastin-degrading peptides, collagen-degrading peptides, hydrolyzed collagen, hydroxypropylammonium chloride hydrolyzed collagen, conchiolin-degrading peptides, hydrolyzed conchiolin, silk protein-degrading peptides, hydrolyzed silk, sodium lauroyl hydrolyzed silk, soy protein-degrading peptides, hydrolyzed soy protein, wheat protein, wheat protein-degrading peptides, hydrolyzed wheat protein, casein-degrading peptides, and acylated peptides (such as palmitoyl oligopeptides, palmitoyl pentapeptides, and palmitoyl tetrapeptides).

[0067] Examples of amino acids or their derivatives include betaine (trimethylglycine), proline, hydroxyproline, arginine, lysine, serine, glycine, alanine, phenylalanine, β-alanine, threonine, glutamic acid, glutamine, asparagine, aspartic acid, cysteine, cystine, methionine, leucine, isoleucine, valine, histidine, taurine, γ-aminobutyric acid, γ-amino-β-hydroxybutyric acid, carnitine, carnosine, and creatine.

[0068] Examples of cell-activating components include amino acids such as γ-aminobutyric acid and ε-aminocaproic acid; vitamins such as retinol, thiamine, riboflavin, pyridoxine hydrochloride, and pantothenic acids; α-hydroxy acids such as glycolic acid and lactic acid; tannins; flavonoids; saponins; allantoin; and photosensitizer 301.

[0069] Examples of anti-aging ingredients include pangamic acid, kinetin, ursolic acid, turmeric extract, sphingosine derivatives, silicon, silicic acid, N-methyl-L-serine, and mevalonolactone.

[0070] Examples of blood circulation-promoting ingredients include those derived from plants (e.g., ginseng, angelica tree, arnica, ginkgo, fennel, laurel, watercress, chamomile, Roman chamomile, carrot, gentian, burdock, rice, hawthorn, shiitake mushroom, hawthorn, juniper, cinnamon, gentian, thyme, clove, dried tangerine peel, angelica, peach kernel, spruce, carrot, garlic, butcher's broom, grape, peony, horse chestnut, lemon balm, yuzu, coix seed, rosemary, rosehip, peach, apricot, walnut, or corn); glucosyl hesperidin, etc.

[0071] Examples of keratin-softening ingredients include urea, salicylic acid, glycolic acid, gluconic acid, fruit acids, phytic acid, lanolin, lactic acid, lactate salts, citric acid, and sulfur.

[0072] Examples of whitening ingredients include arbutin, hydroquinone, kojic acid, ellagic acid, phytic acid, rucinol, chamomile ET, ascorbic acid or its derivatives, vitamin E or its derivatives, pantothenic acid or its derivatives, and plant-derived ingredients with whitening properties (e.g., plant extracts or essential oils).

[0073] Examples of astringent components include metal salts such as alum, chlorohydroxyaluminum, aluminum chloride, allantoin aluminum salt, and aluminum potassium sulfate; organic acids such as tannic acid, citric acid, lactic acid, and succinic acid; and menthol and ethanol.

[0074] Examples of UV-absorbing components include 2-ethylhexyl paramethoxycinnamate, 2-[4-(diethylamino)-2-hydroxybenzoyl]hexyl benzoate, 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]-1,3,5-triazine, 2-ethylhexyl dimethoxybenzylidene oxoimidazolidinepropionate, 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, t-butyl methoxydibenzoylmethane, ethylhexyl dibenzylidene dioxoimidazolidinepropylonate, etorhexyl triazoline, para-aminobenzoic acid and its derivatives, octyl paradimethylaminobenzoate, ethylene glycol satyrylate, and dihydroxybenzophenone.

[0075] Examples of ultraviolet scattering components include inorganic compounds such as titanium dioxide, iron oxide, cerium oxide, zirconium oxide, titanium silicate, anhydrous silicic acid, cerium silicate, and hydrated silicic acid; these inorganic compounds coated with hydrated silicic acid, aluminum hydroxide, or inorganic powders such as mica and talc; these inorganic compounds compounded with resin powders such as polyamide, polyethylene, polyester, polystyrene, or nylon; and these inorganic compounds treated with silicone oil, aluminum fatty acid salts, etc.

[0076] Cleansing ingredients include, for example, polyoxyalkylene alkyl (or alkenyl) ether sulfates, alkyl (or alkenyl) sulfates, higher fatty acid salts (palmitic acid, lauric acid, myristic acid, stearic acid, etc.), ether carboxylates, amide ether carboxylates, alkyl phosphate esters, N-acyl amino acid salts (sodium N-lauroyl aspartate, potassium hydroxide / potassium N-coconut oil fatty acid acyl glutamate, sodium coconut oil fatty acid acylglycine, myristoyl glutamic acid, etc.), and polyoxyalkylene fatty acid amide ether sulfates. Examples include anionic surfactants such as acylated isethionates and acylated taurates; cationic surfactants such as mono- or di-long-chain alkyl quaternary ammonium salts having a linear or branched long-chain alkyl group, which may have alkylene oxides added; and amphoteric surfactants such as carbobetine, sulfobetine, imidazolinium betaine (2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolium betaine, N-coconut oil fatty acid acyl-N-carboxymethoxyethyl-N-carboxymethylethylenediamine disodium, etc.) and amidebetaine.

[0077] Other active ingredients may be used individually or in combination of two or more.

[0078] The pH of the topical composition according to this embodiment can be, for example, 4 or higher, 5 or higher, 5.5 or higher, or 6 or higher. Alternatively, the pH of the topical composition according to this embodiment can be, for example, 8 or lower, 7 or lower, 7.5 or lower, 6 or lower, or 5.5 or lower.

[0079] The viscosity of the topical composition according to this embodiment can be appropriately set depending on the type or content of each component, its use, and its formulation. Viscosity (at 25°C) as used herein refers to the viscosity measured using a single-cylinder rotational viscometer (Brookfield viscometer) in accordance with the viscosity measurement method described in the general test methods of the 18th edition of the Japanese Pharmacopoeia. Specifically, it refers to the value measured using a TVB-H type viscometer (manufactured by Toki Sangyo Co., Ltd.), and the selection of conditions such as the rotor and rotation speed shall be in accordance with the instruction manual of this instrument, and the viscosity at 25°C shall be measured.

[0080] The following is a description of a single-cylinder rotational viscometer. A single-cylinder rotational viscometer is a viscometer that measures the torque when a cylinder in a liquid is rotated at a constant angular velocity. The viscosity η of the liquid is calculated by the following formula after experimentally determining the apparatus constant KB using a viscometer calibration standard solution. η = KB × T / ω η: Viscosity of liquid (mPa·s) KB: Equipment constant (rad / cm 3 ) ω: Angular velocity (rad / s) T: Torque acting on the cylindrical surface (10 -7 N·m)

[0081] The viscosity of the topical composition according to this embodiment may be, for example, the viscosity 1 (25°C) measured at 25°C at 5 rpm using a TVB-H type viscometer (manufactured by Toki Sangyo Co., Ltd.) with an H6 rotor. In that case, the viscosity 1 (25°C) of the topical composition according to this embodiment can be, for example, 0.1 Pa·s or more, 1 Pa·s or more, 5 Pa·s or more, 10 Pa·s or more, 30 Pa·s or more, or 50 Pa·s or more. Alternatively, the viscosity 1 (25°C) of the topical composition according to this embodiment can be, for example, 300 Pa·s or less, 200 Pa·s or less, 100 Pa·s or less, 80 Pa·s or less, 60 Pa·s or less, 50 Pa·s or less, or 20 Pa·s or less.

[0082] The viscosity of the topical composition according to this embodiment may be, for example, the viscosity 2 (25°C) measured at 25°C at 50 rpm using a TVB-H type viscometer (manufactured by Toki Sangyo Co., Ltd.) with an H6 rotor. In that case, the viscosity 2 (25°C) of the topical composition according to this embodiment can be, for example, 0.1 Pa·s or more, 1 Pa·s or more, 5 Pa·s or more, 10 Pa·s or more, 30 Pa·s or more, or 50 Pa·s or more. Alternatively, the viscosity 2 (25°C) of the topical composition according to this embodiment can be, for example, 300 Pa·s or less, 200 Pa·s or less, 100 Pa·s or less, 80 Pa·s or less, 60 Pa·s or less, 50 Pa·s or less, or 20 Pa·s or less.

[0083] The method of using the topical composition according to this embodiment varies depending on the condition, age, and gender of the person using it, but examples include the following. The method of use is to apply an appropriate amount (for example, 0.05 to 5 g, preferably 0.5 to 1 g) of the topical composition according to this embodiment to the skin several times a day (for example, 1 to 5 times, preferably 1 to 3 times, more preferably 1 time). The application period of the topical composition may be, for example, 1 to 6 months, preferably 3 to 6 months. The topical composition according to this embodiment can be used for the therapeutic effect of acne. Applicable application sites include the skin of the face, hands, feet, head, neck, chest, armpits, back, waist, back of the elbows, and back of the knees, with the face being preferred.

[0084] One embodiment of the present invention provides a method for imparting to a composition containing (A) adapalene an effect that reduces the enhancement of discomfort during application caused by component (A), comprising adding (B) one or more selected from the group consisting of polyethylene glycol and glycerin to the above composition. Component (A) and component (B) are as described above.

[0085] The above-mentioned effect of reducing the enhancement of discomfort during application by component (A) in the above-mentioned composition may also be an effect of reducing the enhancement of discomfort during application by component (A) in comparison to the enhancement of discomfort by component (A) when adapalene and propylene glycol are applied to the above-mentioned composition.

[0086] One embodiment of the present invention provides a method for reducing the enhancement of discomfort caused by component (A) during application in a composition containing (A) adapalene, comprising adding (B) one or more selected from the group consisting of polyethylene glycol and glycerin. Component (A) and component (B) are as described above.

[0087] The method may also be a method that reduces the enhancement of discomfort caused by component (A) during application, compared to the enhancement of discomfort caused by component (A) during application of adapalene and propylene glycol.

[0088] One embodiment of the present invention provides an agent for enhancing or reducing discomfort during application of an adapalene-containing topical composition containing one or more selected from the group consisting of polyethylene glycol and glycerin. The polyethylene glycol and glycerin are as described above.

[0089] The enhancer / reduction agent may be an agent for reducing the enhancement of discomfort caused by topical compositions containing adapalene, compared to propylene glycol.

[0090] One embodiment of the present invention provides an adapalene-mediated inhibitor of TRPV1 activation enhancement, which contains one or more selected from the group consisting of polyethylene glycol and glycerin. The polyethylene glycol and glycerin are as described above.

[0091] The enhancement-reducing agent may be an agent for reducing the enhancement of TRPV1 activity by adapalene compared to propylene glycol. [Examples]

[0092] The present invention will be described more specifically below based on examples. However, the present invention is not limited to the following examples.

[0093] [Test Example 1. TRPV1 Activity Evaluation Test] Pain and burning sensations caused by several retinoids are known to be related to the activation of TRPV1. However, it was not known that adapalene activates TRPV1 until the inventors discovered this. Focusing on this, this example evaluates the effect of adapalene on the activation of TRPV1. When TRPV1 is activated, Ca2+ enters the cell. 2+ When it flows in, intracellular Ca2+ The concentration increases. In this example, the increase in intracellular Ca caused by the activation of TRPV1 by adapalene 2+ concentration was measured using Ca 2+ -sensitive fluorescent dye Fluo-8 AM.

[0094] The composition of the assay buffer used and the cells are as follows. · Composition of assay buffer: 50 mL of Hank's BSS, 10 mL of 1M 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES), 20 mL of 25 mM CaCl2, 5 mL of 10% albumin derived from bovine serum, and 410 mL of sterile water · Cells: T-REx293 Cells

[0095] The medium was removed from the cultured cells, the cells were washed with assay buffer, then Fluo-8 AM (3 μM) (manufactured by AAT Bioquest) diluted with assay buffer was added, and incubation was performed at 37°C for 1 hour. Thereafter, the Fluo-8 AM solution was removed, the cells were washed with assay buffer, and then assay buffer was added to the cells again. Using FlexStation (registered trademark) III (manufactured by Molecular Devices), the change in fluorescence intensity from 0 seconds to 150 seconds at 37°C was measured (wavelength: excitation 490 nm, cutoff 515 nm, emission 525 nm). 30 seconds after the start of measurement, propylene glycol (PG), polyethylene glycol (PEG; number average molecular weight: 400), concentrated glycerin, butylene glycol (BG), or dipropylene glycol (DPG) alone, or adapalene alone, or various polyhydric alcohols and adapalene were added to each well.

[0096] Table 1 shows the measurement results of TRPV1 activity when various polyhydric alcohols are added alone. Table 3 shows the measurement results of relative fluorescence intensity (RFU) when adapalene alone, polyethylene glycol alone, or polyethylene glycol and adapalene are added. Furthermore, Table 2 shows the measurement results of relative fluorescence intensity (RFU) when adapalene alone, propylene glycol alone, or propylene glycol and adapalene are added.

[0097] The formula for calculating TRPV1 activity is as follows: TRPV1 activity=ΔF / F0 F0 = Fmean(0-25s), ΔF = F80s-F0

[0098] [Table 1]

[0099] As shown in Table 3, when polyethylene glycol and adapalene were added (Example 1-1), the TRPV1 activity was only additively activated by adapalene and polyethylene glycol. On the other hand, as shown in Table 2, when propylene glycol and adapalene were added (Comparative Example 1-1), the TRPV1 activity was synergistically activated by propylene glycol and adapalene. Furthermore, the TRPV1 activity when polyethylene glycol and adapalene were added was 0.69 (0.65 / 0.94) compared to the TRPV1 activity when adapalene and propylene glycol were added (with the latter set to 1).

[0100] [Table 2]

[0101] [Table 3]

[0102] From these results, it was found that polyethylene glycol can suppress the enhancement of discomfort during application caused by adapalene. This can be understood from the fact that the TRPV1 activity when polyethylene glycol and adapalene are added is 0.69, compared to the TRPV1 activity when adapalene and propylene glycol are added (which is set to 1). Furthermore, since the TRPV1 activity of the raw materials alone is lower than that of propylene glycol, it was inferred that glycerin can also suppress the enhancement of discomfort during application caused by adapalene.

[0103] [Test Example 2. Sensory Evaluation Test] The compositions (gels) of Comparative Example 2-1 and Examples 2-1 to 2-2 shown in Table 4 were prepared by conventional methods, and their pH and viscosity were measured. Viscosity was measured using a TVB-H type viscometer (manufactured by Toki Sangyo Co., Ltd.) with an H6 rotor at 5 rpm. All units in Table 4 are in weight percent. The compositions of Comparative Example 2-1 or each of the Examples (Examples 2-1 to 2-2) were applied to the faces (cheeks) and necks of five healthy adults, and sensory evaluations were conducted for irritation, other discomfort, and moisturizing sensation from immediately after application to 5 minutes later. The sensory evaluation was performed on an 11-point scale from 0 to 10, with the evaluation value of Comparative Example 2-1 set to 5, where 0 means no sensation and 10 means a sensation was felt. The average values ​​were calculated and the results of the comparison are shown in Table 5.

[0104] [Table 4]

[0105] [Table 5]

[0106] As shown in Table 5, the results demonstrated that combining adapalene with polyethylene glycol or adapalene with glycerin suppressed the irritation and other post-application skin discomfort caused by adapalene when combined with propylene glycol, and further improved moisturizing properties. In other words, it was confirmed in humans that component (B) of the present invention can suppress discomfort caused by adapalene more effectively than when combined with propylene glycol.

[0107] [Examples of formulations] The compositions (gel formulations) of Formulation Examples 1 to 16 shown in Tables 6 and 7 were prepared by conventional methods, and their pH was measured. All units in Tables 6 and 7 are in weight percent.

[0108] [Table 6]

[0109] [Table 7]

Claims

1. A topical composition comprising (A) adapalene and (B) one or more selected from the group consisting of polyethylene glycol and glycerin.

2. The topical composition according to claim 1, comprising 0.001 to 1% by weight of component (A).

3. The topical composition according to claim 1 or 2, comprising 0.001 to 30% by weight of component (B).

4. The topical composition according to claim 1 or 2, wherein the ratio of the content (weight%) of component (B) to the content (weight%) of component (A) is 0.001 to 300.

5. A method for imparting to a composition containing (A) adapalene an effect that reduces the enhancement of discomfort during application caused by component (A), comprising (B) adding one or more selected from the group consisting of polyethylene glycol and glycerin.

6. A method for reducing the enhancement of discomfort caused by component (A) during application in a composition comprising (A) a composition containing adapalene and (B) one or more selected from the group consisting of polyethylene glycol and glycerin.

7. An agent for enhancing or reducing discomfort during application of an adapalene-containing topical composition, comprising one or more selected from the group consisting of polyethylene glycol and glycerin.

Citation Information

Patent Citations

  • Acne treating pharmaceutical composition

    JP2015081244A